Thomas A. Raffin - 05 May 2022 Form 4 Insider Report for LUMOS PHARMA, INC.

Role: Director
Signature: /s/ Ryan Trytten, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 05 May 2022
Net transactions value: $0
Form type: 4
Filing time: 09 May 2022, 17:10:34 UTC
Previous filing: 16 Sep 2021
Next filing: 03 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LUMO	Stock Option (Right to Buy)	Award	$0	+3,431		$0.000000	3,431	05 May 2022	Common Stock	3,431	$8.18	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant.

Content

Grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant.